The OPAL study

May 13, 2024
  • Trial status: Closed to recruitment in the UK
  • Trial ID: NCT06380335

What is OPAL?

OPAL is an observational study sponsored by Resolution Therapeutics. 11 hospitals across England and Scotland are participating in the study.

OPAL stands for Observational Study in PArticipants with Liver Cirrhosis.

 

[sp_easyaccordion id=”62474″]

 

What is the reason for OPAL?

Advanced cirrhosis can progress in different ways for different people. We do not fully understand how the disease develops after someone has their first liver decompensation event.


[sp_easyaccordion id=”62480″]

 

How could OPAL help?

The OPAL trial will collect data from routine hospital visits, medical records, and blood tests. This data will help doctors and scientists understand how to better care for people with advanced cirrhosis.

The research will also help companies developing new medicines and treatments. OPAL is sponsored by a company called Resolution Therapeutics.

This is an innovative biotech company with labs in Edinburgh and London. They are working on developing a novel treatment for advanced cirrhosis. The data collected in OPAL will help with future studies of their new treatment. If you decide to participate in OPAL, you would be contributing to medical research that may lead to improved treatments for people like you.

 

Taking part in the OPAL study

Can I take part in OPAL?

OPAL is focused on people with “decompensated cirrhosis”. This study is no longer looking for additional participants to join.

There are currently 11 hospitals across England and Scotland participating in the study and participants enrolled in the study are in the follow up period.

 

 

More news

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

Potential for hundreds more liver transplants after NICE recommends new life-saving liver procedure for NHS use

The British Liver Trust welcomes the news that hundreds more liver transplants could be carried out after a new procedure that supplies a donor liver with oxygen before removal was approved by NICE for use in the NHS.   In-situ ...
New hope for people living with MASH as two treatments receive MHRA approval

New hope for people living with MASH as two treatments receive MHRA approval

People living with metabolic dysfunction-associated steatohepatitis (MASH) have received encouraging news, with the UK medicines regulator approving two treatments for the condition within the past month. The Medicines and Healthcare ...
New Lancet Commission Highlights the Vital Role of Primary Care in Tackling Liver Disease

New Lancet Commission Highlights the Vital Role of Primary Care in Tackling Liver Disease

A major new Lancet Gastroenterology & Hepatology Commission, published today, has shone a spotlight on the crucial role that primary care can play in preventing, detecting and managing liver disease. We were proud to contribute to ...
No results found.
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.